Nothing Special   »   [go: up one dir, main page]

GT200600108A - Control de plagas - Google Patents

Control de plagas

Info

Publication number
GT200600108A
GT200600108A GT200600108A GT200600108A GT200600108A GT 200600108 A GT200600108 A GT 200600108A GT 200600108 A GT200600108 A GT 200600108A GT 200600108 A GT200600108 A GT 200600108A GT 200600108 A GT200600108 A GT 200600108A
Authority
GT
Guatemala
Prior art keywords
union
fragments
control
new
antibodies
Prior art date
Application number
GT200600108A
Other languages
English (en)
Inventor
Patricia Jane Cayley
Andrew John Dinsmore
Fergus Gerard Paul Earley
Claire Judith Anne Sadler
Jason Leigh Vincent
Original Assignee
Syngenta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0505054A external-priority patent/GB0505054D0/en
Priority claimed from GB0600719A external-priority patent/GB0600719D0/en
Application filed by Syngenta Ltd filed Critical Syngenta Ltd
Publication of GT200600108A publication Critical patent/GT200600108A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Catching Or Destruction (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

LA PRESENTE INVNEICÓN SE REFIERE A NUEVOS AGENTES PARA EL CONTROL DE ROEDORES QUE COMPRENDEN ANTICUERPOS, O SUS FRAGMENTOS DE UNIÓN AL ANTÍGENO, QUE SE UNEN A PROTEÍNAS EXPRESADAS EN ROEDORES Y EN PARTICULAR ANTICUERPOS O FRAGMENTOS DE UNIÓN AL ANTÍGENO QUE SE UNEN A PROTEÍNAS EXPRESADAS EN EL TRACTO GASTROINTESTINAL (GI) DE ROEDORES, COMO ASÍ TAMBIÉN A MÉTODOS PARA PREPARAR TALES AGENTES DE CONTROL DE ROEDORES NUEVOS. LA INVENCIÓN ADEMÁS SE EXTIENDE A NUEVOS ANTICUERPOS Y FRAGMENTOS DE UNIÓN AL ANTÍGENO PARA UTILIZAR EN EL CONTROL DE ROEDORES COMO ASÍ TAMBIÉN A MÉTODOS PARA CONTROLAR LOS ROEDORES A TRAVÉS DEL USO DE TALES ANTICUERPOS, FRAGMENTOS DE UNIÓN AL ANTÍGENO Y NUEVOS AGENTES PARA EL CONTROL DE ROEDORES.
GT200600108A 2005-03-11 2006-03-10 Control de plagas GT200600108A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0505054A GB0505054D0 (en) 2005-03-11 2005-03-11 Antibodies
GB0600719A GB0600719D0 (en) 2006-01-13 2006-01-13 Pest control

Publications (1)

Publication Number Publication Date
GT200600108A true GT200600108A (es) 2006-10-25

Family

ID=36216798

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600108A GT200600108A (es) 2005-03-11 2006-03-10 Control de plagas

Country Status (17)

Country Link
US (1) US8349328B2 (es)
EP (1) EP1863849B1 (es)
JP (1) JP5032458B2 (es)
AR (1) AR052502A1 (es)
AT (1) ATE507245T1 (es)
AU (1) AU2006221823B2 (es)
BR (1) BRPI0608838A2 (es)
CA (1) CA2599465A1 (es)
DE (1) DE602006021552D1 (es)
DK (1) DK1863849T3 (es)
GT (1) GT200600108A (es)
MX (1) MX2007010899A (es)
MY (1) MY149858A (es)
PL (1) PL1863849T3 (es)
PT (1) PT1863849E (es)
TW (1) TWI396695B (es)
WO (1) WO2006095128A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0721937D0 (en) 2007-11-08 2007-12-19 Secr Defence Rodenticide
ITBO20090012A1 (it) * 2009-01-15 2010-07-16 Vincenza Dolo Composizione biocida e suo uso.
US9200251B1 (en) 2011-03-31 2015-12-01 David Gordon Bermudes Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith
ITBO20120094A1 (it) * 2012-02-28 2013-08-29 Vincenza Dolo Composizione biocida
GB201221069D0 (en) * 2012-11-23 2013-01-09 Univ Reading Control method
WO2014127342A1 (en) * 2013-02-18 2014-08-21 University Of Maryland, Baltimore Peptide additives for enhancing acceptance and ingestion of edibles by rodents and uses thereof
MX2018014382A (es) * 2016-05-23 2019-08-12 Gries Gerhard Atrayentes para roedores.
EP3415010A1 (en) * 2017-06-13 2018-12-19 Agrosavfe Nv Insect-controlling polypeptides and methods

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2633834A1 (de) * 1975-08-19 1977-03-03 Lipha Nagetierbekaempfungsmittel und dessen verwendung
US4851332A (en) 1985-04-01 1989-07-25 Sloan-Kettering Institute For Cancer Research Choriocarcinoma monoclonal antibodies and antibody panels
BE1000534A5 (fr) * 1987-05-15 1989-01-17 Billen E Ets Sprl Composition pour l'extermination d'animaux rongeurs.
US5290914A (en) * 1988-04-28 1994-03-01 Mycogen Corporation Hybrid diphtheria-B.t. pesticidal toxins
EP0347227B1 (en) * 1988-06-17 1993-11-24 E.I. Du Pont De Nemours And Company Pesticidal compositions
US6326467B1 (en) * 1989-02-23 2001-12-04 Colorado State University Research Foundation Hormone-recombinant toxin compounds and methods for using same
US5237051A (en) * 1990-12-06 1993-08-17 Vanderbilt University Purified enterotoxin receptor protein
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE452975T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
US5849870A (en) 1993-03-25 1998-12-15 Novartis Finance Corporation Pesticidal proteins and strains
IL116436A (en) 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND
TW585921B (en) * 1997-07-10 2004-05-01 Res Dev Foundation Species specific monoclonal antibodies and phage displayed Fab and scFV fragments for fragments for targeted destruction of imported fire ants
ATE535154T1 (de) 1998-03-12 2011-12-15 Vhsquared Ltd Produkten die inaktivierte hefen oder schimmel enthalten, die auf ihrer aussenoberfläche aktive antikörper haben
US6492498B1 (en) * 1999-11-15 2002-12-10 Regents Of The University Of Minnesota Multimeric immunotoxins
AU2001236806A1 (en) 2000-02-10 2001-08-20 Research Development Foundation Targeted destruction of pests
CA2380443C (en) 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
GB0015935D0 (en) * 2000-06-30 2000-08-23 Univ Sheffield Vaccine
EP1433793A4 (en) * 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
US20050009188A1 (en) * 2002-09-19 2005-01-13 Kitto G. Barrie Animal immunocontraceptives expressed in plants and uses thereof

Also Published As

Publication number Publication date
DE602006021552D1 (de) 2011-06-09
US20100158892A1 (en) 2010-06-24
TW200643031A (en) 2006-12-16
US8349328B2 (en) 2013-01-08
BRPI0608838A2 (pt) 2010-02-02
CA2599465A1 (en) 2006-09-14
EP1863849B1 (en) 2011-04-27
MX2007010899A (es) 2007-12-06
WO2006095128A3 (en) 2006-11-30
PL1863849T3 (pl) 2011-09-30
PT1863849E (pt) 2011-05-10
JP2008532986A (ja) 2008-08-21
MY149858A (en) 2013-10-31
JP5032458B2 (ja) 2012-09-26
AR052502A1 (es) 2007-03-21
ATE507245T1 (de) 2011-05-15
AU2006221823A1 (en) 2006-09-14
EP1863849A2 (en) 2007-12-12
WO2006095128A2 (en) 2006-09-14
AU2006221823B2 (en) 2011-06-09
TWI396695B (zh) 2013-05-21
DK1863849T3 (da) 2011-08-08

Similar Documents

Publication Publication Date Title
GT200600108A (es) Control de plagas
CU20120095A7 (es) Antagonistas de pcsk9
CY1118576T1 (el) Πρωτεϊνες δεσμευομενες με αντιγονο ανθρωπινης il-23
CL2012000229A1 (es) Anticuerpo humano aislado o un fragmento del mismo de unión al antígeno, que se une específicamente a la angiopoyetina-2 humana (hang-2) pero que no se une sustancialmente a la hang-1; composición farmacéutica que lo comprende; y su uso para el tratamiento de un tumor, hipertensión, diabetes, edema, enfermedad renal u ocular.
CO6231038A2 (es) Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos
CR20130621A (es) Anticuerpos anti-angptl3 y usos de los mismos
PE20200152A1 (es) Receptores de union a antigeno mejorados
GT200900121A (es) Moleculas de enlace de lingo y uso farmaceutico
MX2017012352A (es) Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos.
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
CY1114658T1 (el) Πρωτεϊνες δεσμευσης αντιγονου του αυξητικου παραγοντα τυπου επιδερμικου αυξητικου παραγοντα προσδεσης στην ηπαρινη
WO2016210365A3 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
PA8718601A1 (es) Anticuerpos anti-5t4 y sus usos
GT201000148A (es) Anticuerpos antimesotelina y usos de los mismos
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
PE20110306A1 (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3)
PE20120549A1 (es) Proteinas biespecificas de union a antigenos
EA201700111A1 (ru) Полипептидные конструкции и их применение
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
CR20130112A (es) Polipéptidos que enlazan miostatina, composiciones y métodos
ECSP13012402A (es) Inmunoglobulinas con dominio variable dual y su uso
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
EA201390254A1 (ru) Модифицированные полипептиды релаксина и их применение